<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835105</url>
  </required_header>
  <id_info>
    <org_study_id>4261-008</org_study_id>
    <nct_id>NCT02835105</nct_id>
  </id_info>
  <brief_title>A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Safety and Pharmacokinetic Study of Ascending Doses of CB-183,315 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of a single
      oral dose of surotomycin (CB-183,315) at ascending dose levels when given to healthy males
      and females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with an Adverse Event (AE)</measure>
    <time_frame>Up to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued study due to an AE</measure>
    <time_frame>Up to Day 9</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Clostridium Difficile Associated Diarrhea (CDAD)</condition>
  <arm_group>
    <arm_group_label>Surotomycin 0.5 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 0.5 g surotomycin in hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surotomycin 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 1 g surotomycin in hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surotomycin 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 2 g surotomycin in hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surotomycin 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 4 g surotomycin in hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single oral dose of placebo for surotomycin in hard gelatin capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surotomycin</intervention_name>
    <description>A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules</description>
    <arm_group_label>Surotomycin 0.5 g</arm_group_label>
    <arm_group_label>Surotomycin 1 g</arm_group_label>
    <arm_group_label>Surotomycin 2 g</arm_group_label>
    <arm_group_label>Surotomycin 4 g</arm_group_label>
    <other_name>CB-183,315</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single oral dose of placebo for surotomycin in hard gelatin capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has no evidence of prior chronic gastrointestinal inflammatory disease such as
             inflammatory bowel disease or gastroesophageal reflux disease documented on endoscopy

          -  Electrocardiogram (ECG) shows no clinically significant abnormalities

          -  Is able to swallow capsules

          -  is in good health

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Has had Clostridium (C.) difficile disease within 1 year prior to entry into the study

          -  Has received an investigational drug or participated in any experimental procedure
             within1 month prior to study entry and at least 6 half lives from last intake of study
             drug

          -  Participants 18 to 49 years of age had taken any regular, prescribed, or
             over-the-counter medication

          -  Has any significant concurrent therapies

          -  Has a positive drug screen

          -  Has a positive human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C screen

          -  Has given more than 450 mL of blood (one unit) in the 60 days preceding screening

          -  Is an active intravenous drug user or abuses alcohol

          -  Has had a malignancy within the last 5 years

          -  Has inadequate protection against pregnancy during the conduct of the study and until
             1 month after last dose of study drug

          -  Has received any antibiotics within 30 days prior to first dose of study drug

          -  Has been hospitalized within the past 30 days prior to Study Day 1

          -  Has known hypersensitivity to daptomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

